Nextbiotix is a preclinical stage biotechnology company developing mono Live Biotherapeutics involved in inflammatory bowel diseases. NBX1650, is a mono-strain microbial product candidate using Faecalibacterium prausnitzii. F. prausnitzii displays very strong anti-inflammatory effects and plays a central role in modulating immune activity in the gut.

We are very honored to have been chosen by Nextbiotix for this essential development. We are very confident in the quality of the R&D team and also in the value of this very innovative project. It is in the spirit of 3Biotech to be the partner of choice for innovation companies.